Literature DB >> 33707083

Quality of life in Cushing's syndrome.

Margot Mc Bride1, Iris Crespo2, Susan M Webb3, Elena Valassi4.   

Abstract

Measurement of Health-Related Quality of Life (HRQoL) is emerging as an important clinical endpoint which complements diagnostic workup and contributes to place patients at the centre of the decision-making process through the recognition of their needs, concerns, goals and expectations. Chronic excessive cortisol exposure in Cushing's syndrome (CS) causes severe physical and psychological morbidity which invariably affects HRQoL during the active phase of the disease and even after successful treatment. This sustained deterioration of patient's wellbeing is partly related to the persistence of several features associated with prior cortisol excess, including affective disorders, cognitive dysfunctions and negative illness perception. The aim of this review is to summarize the most recent evidence on HRQoL in CS, including the main determinants of its impairment and the results of some educational programs specifically addressed to improve patient's coping abilities. The preliminary results of an unpublished survey on patient's unmet needs will also be presented.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cushing’s diseases; Cushing’s syndrome; educational programs; health-related quality of life; neuropsychiatric dysfunctions; unmet needs

Year:  2021        PMID: 33707083     DOI: 10.1016/j.beem.2021.101505

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  4 in total

Review 1.  Consensus on diagnosis and management of Cushing's disease: a guideline update.

Authors:  Maria Fleseriu; Richard Auchus; Irina Bancos; Anat Ben-Shlomo; Jerome Bertherat; Nienke R Biermasz; Cesar L Boguszewski; Marcello D Bronstein; Michael Buchfelder; John D Carmichael; Felipe F Casanueva; Frederic Castinetti; Philippe Chanson; James Findling; Mônica Gadelha; Eliza B Geer; Andrea Giustina; Ashley Grossman; Mark Gurnell; Ken Ho; Adriana G Ioachimescu; Ursula B Kaiser; Niki Karavitaki; Laurence Katznelson; Daniel F Kelly; André Lacroix; Ann McCormack; Shlomo Melmed; Mark Molitch; Pietro Mortini; John Newell-Price; Lynnette Nieman; Alberto M Pereira; Stephan Petersenn; Rosario Pivonello; Hershel Raff; Martin Reincke; Roberto Salvatori; Carla Scaroni; Ilan Shimon; Constantine A Stratakis; Brooke Swearingen; Antoine Tabarin; Yutaka Takahashi; Marily Theodoropoulou; Stylianos Tsagarakis; Elena Valassi; Elena V Varlamov; Greisa Vila; John Wass; Susan M Webb; Maria C Zatelli; Beverly M K Biller
Journal:  Lancet Diabetes Endocrinol       Date:  2021-10-20       Impact factor: 32.069

Review 2.  Quality of life impairment after a diagnosis of Cushing's syndrome.

Authors:  Susan M Webb; Elena Valassi
Journal:  Pituitary       Date:  2022-06-29       Impact factor: 3.599

Review 3.  Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome.

Authors:  Xin He; James W Findling; Richard J Auchus
Journal:  Pituitary       Date:  2022-04-26       Impact factor: 3.599

4.  Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension.

Authors:  Maria Fleseriu; John Newell-Price; Rosario Pivonello; Akira Shimatsu; Richard J Auchus; Carla Scaroni; Zhanna Belaya; Richard A Feelders; Greisa Vila; Ghislaine Houde; Rama Walia; Miguel Izquierdo; Michael Roughton; Alberto M Pedroncelli; Beverly M K Biller
Journal:  Eur J Endocrinol       Date:  2022-09-16       Impact factor: 6.558

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.